US 11,833,195 B2
Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
Jens Hukelmann, Tuebingen (DE); Heiko Schuster, Tuebingen (DE); Ricarda Hannen, Tuebingen (DE); Christoph Schraeder, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Franziska Hoffgaard, Tuebingen (DE); Daniel Johannes Kowalewski, Tuebingen (DE); and Oliver Schoor, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Sep. 29, 2021, as Appl. No. 17/489,557.
Claims priority of provisional application 63/084,963, filed on Sep. 29, 2020.
Prior Publication US 2022/0111022 A1, Apr. 14, 2022
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01)
CPC A61K 39/0011 (2013.01) [A61P 35/00 (2018.01); C07K 14/705 (2013.01); C07K 14/70539 (2013.01); A61K 39/00 (2013.01); A61K 2039/5158 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A peptide consisting of the amino acid sequence of ILDSTTIEI (SEQ ID NO: 1) in the form of
a pharmaceutically acceptable salt.